Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

S. L. Chan, M. Kudo, B. Sangro, R. K. Kelley, J. Furuse,J-W. Park, P. Sunpaweravong, A. Fasolo,T. Yau, T. Kawaoka,A-L. Cheng,S. Azevedo,M. E. Reig Monzon,E. Assenat,M. Yarchoan,A. R. He, M. Makowsky, D. Ran,A. Negro,G. K. Abou-Alfa

ANNALS OF ONCOLOGY（2022）

引用 2|浏览6

暂无评分

摘要

In HIMALAYA (NCT03298451), a single priming dose of T plus D (STRIDE) significantly improved overall survival (OS) vs sorafenib (S), and D was noninferior to S in uHCC (Abou-Alfa et al. NEJM Evid 2022; https://doi.org/10.1056/EVIDoa2100070). Viral aetiology is associated with hepatic impairment in HCC development and may influence immunotherapy activity. Thus, we analysed the impact of viral aetiology on clinical outcomes.

查看译文

关键词

hepatocellular carcinoma,unresectable hepatocellular carcinoma,viral aetiology,tremelimumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要